• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Altimmune, Inc. - Common Stock (NQ:ALT)

    2.900 -0.060 (-2.03%)
    Streaming Delayed Price Updated: 11:29 AM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,063,851
    Open 3.162
    Bid (Size) 2.900 (10,600)
    Ask (Size) 2.910 (21,200)
    Prev. Close 2.960
    Today's Range 2.820 - 3.310
    52wk Range 2.560 - 6.440
    Shares Outstanding 95,598,665
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗
    Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying... 
    Via MarketBeat
    News headline image
    Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗
    Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug... 
    Via MarketBeat

    Performance

    YTD
    -17.4%
    -17.4%
    1 Month
    -1.4%
    -1.4%
    3 Month
    +3.6%
    +3.6%
    6 Month
    -48.8%
    -48.8%
    1 Year
    -28.0%
    -28.0%

    More News

    Read More
    News headline image
    Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
    Via MarketBeat
    News headline image
    Altimmune (ALT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Altimmune Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
    Via Investor Brand Network
    What's going on in today's pre-market session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
    From BioMedWire
    Via GlobeNewswire
    News headline image
    ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
    Via Stocktwits
    News headline image
    Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
    Via The Motley Fool
    News headline image
    Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗
    Via Stocktwits
    News headline image
    Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics ETFs Government Lawsuit
    News headline image
    ALT Stock Rallies 4% — What Does Retail Think? ↗
    Via Stocktwits
    News headline image
    Why Are Investors Looking At Altimmune Stock? ↗
    Via Benzinga
    News headline image
    Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗
    Via Stocktwits
    News headline image
    Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗
    Via Stocktwits
    News headline image
    Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗
    Via Stocktwits
    News headline image
    Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
    Via Benzinga
    News headline image
    ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Altimmune, Inc. - Common Stock publicly traded?
    Yes, Altimmune, Inc. - Common Stock is publicly traded.
    What exchange does Altimmune, Inc. - Common Stock trade on?
    Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Altimmune, Inc. - Common Stock?
    The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
    What is the current price of Altimmune, Inc. - Common Stock?
    The current price of Altimmune, Inc. - Common Stock is 2.900
    When was Altimmune, Inc. - Common Stock last traded?
    The last trade of Altimmune, Inc. - Common Stock was at 07/28/26 11:29 AM ET
    What is the market capitalization of Altimmune, Inc. - Common Stock?
    The market capitalization of Altimmune, Inc. - Common Stock is 277.24M
    How many shares of Altimmune, Inc. - Common Stock are outstanding?
    Altimmune, Inc. - Common Stock has 277M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.